Infographic: Ranibizumab plus panretinal photocoagulation (PRP) versus PRP alone for high-risk proliferative diabetic retinopathy (PDR): the PROTEUS study

Exclusions included patients with HBA1c > 11%, systolic blood pressure >170 mmHg, or diastolic >100 mmHg, intraocular surgery in the preceding 6 months including laser treatments, anti-VEGF in the preceding 3 months, or lesions involving the central macula, such as macular oedema (central retinal thickness >300 µm). Baseline characteristics were similar, except for age (greater in the combined group). Assessments were undertaken by colour fundus photography and fluorescein angiography at months 3, 7 and 12, and assessed by masked graders. Retreatment in either group was at the…